Enanta Pharmaceuticals is getting hip to Hep C. The biotech firm is developing treatments for viral infections including hepatitis C (HCV), a virus that can lead to chronic liver diseases, such as cirrhosis, organ failure, and cancer. The company's first licensed product, which is licensed to  AbbVie, is paritaprevir, is a protease inhibitor for use against HCV. Enanta also has four small molecule drugs under development: glecaprevir, another protease inhibitor for the treatment for HCV; the similar EDP-239 and EDP-494; and EDP-305, which is being studied for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). In late 2014 Enanta discontinued its biodefense antibiotic program.